Cipriana Stefanescu

Prof. Dr. Cipriana Stefanescu

biophysics and medical physics, nuclear medicine, UMF Grigore T Popa Iasi, Iaşi, Romania
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2019 in Materials
Verified
Journal Article
Open access
PDF file
Mihai DanciuMihai Danciu
Mihai Danciu
TATeodora Alexa-Stratulat
Teodora Alexa-Stratulat
CSCipriana Stefanescu
Cipriana Stefanescu
Gianina DodiGianina Dodi
Gianina Dodi
BTBogdan Tamba
Bogdan Tamba
VDVasile Drug
Vasile Drug
The Terahertz’s wavelength is located between the microwave and the infrared region of the electromagnetic spectrum. Because it is non-ionizing and non-invasive, Terahertz (THz)-based detection represents a very attractive tool for repeated assessments, patient monitoring, and follow-up. Cancer acts as the second leading cause of death in many regions, and current predictions estimate a continuous increasing trend. Of all types of tumors, digestive cancers represent an important percentage and their incidence is expected to increase more rapidly than other tumor types due to unhealthy lifestyle habits. Because it can precisely differentiate between different types of molecules, depending on water content, the information obtained through THz-based scanning could have several uses in the management of cancer patients and, more importantly, in the early detection of different solid tumors. The purpose of this manuscript is to offer a comprehensive overview of current data available on THz-based detection for digestive cancers. It summarizes the characteristics of THz waves and their interaction with tissues and subsequently presents available THz-based technologies (THz spectroscopy, THz-tomography, and THZ-endoscope) and their potential for future clinical use. The third part of the review is focused on highlighting current in vitro and in vivo research progress in the field, for identifying specific digestive cancers known as oral, esophageal, gastric, colonic, hepatic, and pancreatic tumors.

2 December 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
WJWAEL JALLOUL
WAEL JALLOUL
VGVlad Ghizdovat
Vlad Ghizdovat
SCStolniceanu Cati-Raluca
Stolniceanu Cati-Raluca
TITeodor Ionescu
Teodor Ionescu
IGIrena Cristina Grierosu
Irena Cristina Grierosu
CSCipriana Stefanescu
Cipriana Stefanescu
The high energy of α emitters, and the strong linear energy transfer that goes along with it, lead to very efficient cell killing through DNA damage. Moreover, the degree of oxygenation and the cell cycle state have no impact on these effects. Therefore, α radioisotopes can offer a treatment choice to individuals who are not responding to β− or gamma-radiation therapy or chemotherapy drugs. Only a few α-particle emitters are suitable for targeted alpha therapy (TAT) and clinical applications. The majority of available clinical research involves 225Ac and its daughter nuclide 213Bi. Additionally, the 225Ac disintegration cascade generates γ decays that can be used in single-photon emission computed tomography (SPECT) imaging, expanding the potential theranostic applications in nuclear medicine. Despite the growing interest in applying 225Ac, the restricted global accessibility of this radioisotope makes it difficult to conduct extensive clinical trials for many radiopharmaceutical candidates. To boost the availability of 225Ac, along with its clinical and potential theranostic applications, this review attempts to highlight the fundamental physical properties of this α-particle-emitting isotope, as well as its existing and possible production methods.

1 April 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
BTB.I. Tamba
B.I. Tamba
ADA. Dondas
A. Dondas
MLM. Leon
M. Leon
ANA.N. Neagu
A.N. Neagu
Gianina DodiGianina Dodi
Gianina Dodi
ATA. Tijani
A. Tijani

8 May 2020 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
CSCipriana Stefanescu
Cipriana Stefanescu
INIonut Nistor
Ionut Nistor
SBStefana Catalina Bilha
Stefana Catalina Bilha
VCVolovat Constantin
Volovat Constantin
VSVolovat Simona
Volovat Simona
ACAdrian Covic
Adrian Covic
Background/objective: Data regarding the nephrotoxicity of the peptide receptor radionuclide therapy (PRRT) with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs (RSA) are inconclusive. We aimed to evaluate the short- and long-term nephrotoxicity following PRRT usage in patients with all types of neuroendocrine tumors (NETs). Methods: A systematic review of observational studies reporting data about nephrotoxicity after treatment with 90Yttrium and 177Lutetium RSA was performed. Data on serum creatinine, creatinine clearance, glomerular filtration rate (GFR) and need for renal replacement therapy were compiled. We included patients with progressive, inoperable symptomatic G1, G2 and G3 different types of NETs. After searching in three electronic databases PubMed, Scopus and the Cochrane Library, from 1 January 1978 to November 2018, data were extracted and summarized using a random-effects model. Results: The final analysis included 34 studies, comprising 5386 participants, enrolling patients with G1, G2, G3 NETs and a follow-up from 12 up to 191 months. Compared with renal function before treatment, measured/estimated glomerular filtration rate (m/eGFR) values changed after PRRT, with a mean annual decrease following PRRT between 2 and 4 mL/min/1.73 m2 suggesting different grades of nephrotoxicity after PRRT. When compared, 90Y-RSA and the 90Y-RSA-177Lu-RSA combination are associated with a higher m/eGFR decline compared to 177Lu-RSA alone. Conclusions: PRRT can be followed by potentially serious long-term nephrotoxicity, despite kidney protection. The use of the quantified renal function combined with a long follow-up period and personalized dosimetry-based PRRT can reduce nephrotoxicity, in order to use the whole PRRT potential in the management of NETs.

15 March 2024 in Journal of Materials Chemistry B
Verified
Journal Article
Open access
PDF file
Cristina Mariana UrituCristina Mariana Uritu
Cristina Mariana Uritu
CACristina Maria Al-Matarneh
Cristina Maria Al-Matarneh
DBDenisse Iulia Bostiog
Denisse Iulia Bostiog
ACAdina Coroaba
Adina Coroaba
VGVlad Ghizdovat
Vlad Ghizdovat
Mariana PintealaMariana Pinteala
Mariana Pinteala
The demand for tailored, disease-adapted, and easily accessible radiopharmaceuticals is one of the most persistent challenges in nuclear imaging precision medicine. In this study, two radiotracers were developed to bind SPECT and PET radionuclides.

11 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SVSimona-Ruxandra Volovat
Simona-Ruxandra Volovat
CLCorina Lupascu-Ursulescu
Corina Lupascu-Ursulescu
LGLILIANA GHEORGHE
LILIANA GHEORGHE
CVConstantin Volovat
Constantin Volovat
DPDiana Ioana Panaite
Diana Ioana Panaite
CVCristian Volovat
Cristian Volovat
Immunotherapy represents a promising strategy for the treatment of cancer, which functions via the reprogramming and activation of antitumor immunity. However, adverse events resulting from immunotherapy that are related to the low specificity of tumor cell-targeting represent a limitation of immunotherapy’s efficacy. The potential of nanotechnologies is represented by the possibilities of immunotherapeutical agents being carried by nanoparticles with various material types, shapes, sizes, coated ligands, associated loading methods, hydrophilicities, elasticities, and biocompatibilities. In this review, the principal types of nanovectors (nanopharmaceutics and bioinspired nanoparticles) are summarized along with the shortcomings in nanoparticle delivery and the main factors that modulate efficacy (the EPR effect, protein coronas, and microbiota). The mechanisms by which nanovectors can target cancer cells, the tumor immune microenvironment (TIME), and the peripheral immune system are also presented. A possible mathematical model for the cellular communication mechanisms related to exosomes as nanocarriers is proposed.